Rucaparib or Physician's Choice in Metastatic Prostate Cancer
Por um escritor misterioso
Descrição
Cancers, Free Full-Text
Accelerating precision medicine in metastatic prostate cancer
Rucaparib or physician's choice in metastatic prostate cancer - UROONCO Prostate Cancer
Rucaparib or Physician's Choice in Metastatic Prostate Cancer
FDA Approves Olaparib, Rucaparib to Treat Prostate Cancer - NCI
When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials - ScienceDirect
ASCO GU 2023: Rucaparib for Metastatic Castration-Resistant Prostate Cancer (mCRPC): TRITON3 Interim Overall Survival and Efficacy of Rucaparib vs Docetaxel or Second-Generation Androgen Pathway Inhibitor Therapy
Prostate cancer and PARP inhibitors: progress and challenges, Journal of Hematology & Oncology
Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study - European Journal of Cancer
ASCO GU 2023: Rucaparib for Metastatic Castration-Resistant Prostate Cancer (mCRPC): TRITON3 Interim Overall Survival and Efficacy of Rucaparib vs Docetaxel or Second-Generation Androgen Pathway Inhibitor Therapy
Rucaparib or Physician's Choice in Metastatic Prostate Cancer
de
por adulto (o preço varia de acordo com o tamanho do grupo)
